PMID: 8604819Apr 1, 1996Paper

Mucinous (colloid) carcinoma of urinary bladder following long-term cyclophosphamide therapy for Waldenstrom's macroglobulinemia

The American Journal of Surgical Pathology
A SiddiquiT Ahmed

Abstract

Carcinoma of the urinary bladder is a known complication of cyclophosphamide therapy. Almost all such cases have been transitional cell carcinomas. We report here the second example of an adenocarcinoma of bladder and the first purely mucinous (colloid) carcinoma of urinary bladder developing after long-term cyclophosphamide therapy. The patient, a 77-year-old woman, had been treated for Waldenstrom's macroglobulinemia for at least 24 years, during which time treatment for this disease varied from 50 to 100 mg per day. The disease terminated in acute myelogenous leukemia, and she died of severe disseminated intravascular coagulopathy associated with hypermacroglobulinemia. The mucinous (colloid) carcinoma of the urinary bladder was an incidental finding at autopsy.

References

Aug 1, 1979·The Journal of Urology·W V FairchildM P Gangai
Apr 1, 1978·Urology·S E SeltzerG P Kearney
May 1, 1978·Urology·R M Pearson, M S Soloway
Aug 7, 1975·The New England Journal of Medicine·R L Wall, K P Clausen
Jul 1, 1975·The Journal of Urology·S H WeinsteinJ D Schmidt
Aug 1, 1975·British Journal of Urology·I D Ansell, J E Castro
Jan 1, 1990·The Journal of Urology·J B ThrasherJ N Wettlaufer
Apr 21, 1988·The New England Journal of Medicine·J Pedersen-BjergaardM M Hansen
Sep 29, 1988·The New England Journal of Medicine·J C O'Keane
Nov 1, 1974·The Journal of Urology·G A Dale, R B Smith
Jul 17, 1971·British Medical Journal·P H Worth
Aug 1, 1980·Urology·C Durkee, R Benson
May 1, 1984·The Journal of Urology·R M EhrlichE R Stiehm
Apr 17, 1982·British Medical Journal·A D HarriesJ Rhodes
Jan 1, 1983·The Journal of Urology·S M Moinuddin, D W Upton
Aug 1, 1983·The Journal of Urology·R G Rowland, J N Eble
Oct 1, 1981·The Journal of Urology·E F FuchsH D Pearse

❮ Previous
Next ❯

Citations

Aug 27, 2002·Journal of Clinical Pathology·A Lopez-BeltranR Montironi
Oct 29, 2002·Leukemia & Lymphoma·Morie A Gertz
Sep 24, 1999·The Urologic Clinics of North America·A Lopez-Beltran
Dec 14, 2016·Histopathology·Antonio Lopez-BeltranLiang Cheng
Jun 2, 2005·American Journal of Hematology·Morie A Gertz

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.